Skip to content

the chandler project

  • Home
  • About
  • Contact
  • Home
  • About
  • Contact

Recent Posts

  • BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia Data Accepted to ENDO 2020

    QED
  • BioMarin – Update for Achondroplasia Associations

    Achondroplasia, BioMarin
  • QED COVID-19 Update

    QED
  • Study of Infigratinib in Children With Achondroplasia

    QED
  • QED Achondroplasia Clinical Update

    QED
  • BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301)

    BioMarin

Posts navigation

1 2 3 Next

Copyright © 2021 the chandler project. All Rights Reserved.

Theme byPortfolio WordPress Themes